source
- BMS CAR-T therapy arlo-cel meets primary endpoint in pivotal multiple myeloma trialBristol Myers Squibb reported that its GPRC5D-directed CAR-T cell therapy, arlo-cel, achieved the primary endpoint in the pivotal Quintessential trial for multiple myeloma. The study enrolled pati…
- Moonwalk Biosciences raises $70M and pivots to RNAi obesity drug developmentMoonwalk Biosciences, a California biotech founded in 2024, announced a new $70 million venture funding round. The capital will support development of its first obesity drug, which uses RNA interf…